\$2.00 per Annum

Single Bominion Copies 20 cts. Monthly ledical

And Ontario Medical Zournal

Volume 39

TORONTO, JULY,

Number 1

ANNOUNCEMENT.

We have added to our list of therapeutic agents and can now supply

Kheumatism Phylacogen

(MODIFIED RHEUMATISM VACCINE)

This is the first of a series of phylacogens, prepared according to the method of DR. A. F. SCHAFER, of Bakersfield, Cal., which we are on the point of offering to the medical profession.

Rheumatism Phylacogen is indicated in all cases of acute and chronic articular rheumatism not due to gonorrheal infection. Its therapeutic use is based upon the theory of multiple infections, the belief being that in most cases of rheumatism, as well as many other infectious diseases, the pathological changes cannot be ascribed entirely to any one species of bacteria, but are due to the combined action of the metabolic products derived from all of the invading pathogenic bacteria.

Rheumatism Phylacogen has been subjected to searching clinical tests during a period of more than a year, the investigations affording conclusive evidence of its value as a therapeutic agent. It is supplied in hermetically sealed glass bulbs of 10 Cc. and is administered subcutaneously.


LITERATURE.

We have in course of preparation a booklet containing a brief history of Rheumatism Phylacogen treatment, together with a detailed description of its clinical application. When issued we shall be pleased to furnish a copy of it to any physician upon receipt of request.

We are the only producers of RHEUMATISM PHYLAC-OGEN; with the co-operation of Dr. Schafer, we conducted the experimental work preliminary to its introduction to the medical profession; and the sole rights of manufacture and sale are vested in us.

WALKERVILLE,

ONTARIO.



^{*}The name Phylacogen (pronounced phy-lac'-o-gen) distinguishes the modified vaccines manufactured by Parke, Davis & Co. according to the process of Dr. A. F. Schafer.